SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Elizabeth E GrayMichelle UlrichAngela EppPatrick YounanDisha SahetyaKelly HensleySean AllredLi-Ya HuangJulie HahnKristen GahnbergPiper M TreutingEsther S TruebloodJohn J GosinkRobert ThurmanSerena WoKellie SpahrEvgenia Jane HaassKatie SneadDannah MillerMary PadillaAlyson J SmithChris FrantzJason P SchrumNatalya NazarenkoShyra J GardaiPublished in: Journal for immunotherapy of cancer (2023)
The immune checkpoint ligand B7-H4 is a promising molecular target expressed by multiple solid tumors. SGN-B7H4V demonstrates robust antitumor activity in preclinical models through multiple potential mechanisms. Altogether, these preclinical data support the evaluation of SGN-B7H4V as a monotherapy in the ongoing phase 1 study of SGN-B7H4V in advanced solid tumors (NCT05194072) and potential future clinical combinations with immunotherapies.